Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients

• Authors: Anne-Claire Mamez, University of Geneva; Amandine Pradier, University of Geneva; Federica Giannotti, University of Geneva; Adrein Petitpas, University of Geneva; Marta Fabra Urdiola, University of Geneva; Diem-Lan Vu, Geneva University Hospitals; Stavroula Masouridi-Levrat, University of Geneva; Sarah Morin, University of Geneva; Carole Dantin, University of Geneva; Dominique Clerc-Renaud, University of Geneva; CS Eberhardt, Emory University; Laurent Kaiser, Geneva University Hospitals; Federico Simonetta, University of Geneva; Yves Chalandon, University of Geneva
• Journal Title: BONE MARROW TRANSPLANTATION
• Volume: Volume 56, Number 12
• Publisher: Springer Nature [academic journals on nature.com] | 2021-09-28, Pages 3094-3096
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1038/s41409-021-01466-9
• Subjects: Political Science, General; Health Sciences, Oncology
• Keywords: SARS-CoV2; vaccination; Antibody responses

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a wide range of hematological diseases but is still associated with significant infection-related morbidity and mortality related to post-transplant immune-deficiency. In the context of the COVID-19 pandemic, several studies have shown that allogeneic HSCT recipients have a higher risk of developing severe forms of COVID-19 and have a higher mortality rate compared to the general population [1, 2]. Induction of protective immunity through prophylactic vaccination is therefore critically important in this high-risk patient population. Although mRNA-based SARS-Cov-2 vaccines are highly effective in inducing protective responses in healthy individuals [3–5], whether they are able to induce protective immunity in allogeneic HSCT recipients is still unknown.